FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2073164009> ?p ?o ?g. }

• W2073164009 endingPage "691.e3" @default.
• W2073164009 startingPage "685" @default.
• W2073164009 abstract "Studies regarding the cross-reactivity and tolerability of alternative cephalosporins in large samples of subjects with an IgE-mediated hypersensitivity to cephalosporins are lacking.We sought to evaluate the possibility of using alternative cephalosporins in subjects with cephalosporin allergy who especially require them.One hundred two subjects with immediate reactions to cephalosporins and positive skin test results to the responsible drugs underwent serum specific IgE assays with cefaclor and skin tests with different cephalosporins. Subjects were classified in 4 groups: group A, positive responses to 1 or more of ceftriaxone, cefuroxime, cefotaxime, cefepime, cefodizime, and ceftazidime; group B, positive responses to aminocephalosporins; group C, positive responses to cephalosporins other than those belonging to the aforementioned groups; and group D, positive responses to cephalosporins belonging to 2 different groups. Group A subjects underwent challenges with cefaclor, cefazolin, and ceftibuten; group B participants underwent challenges with cefuroxime axetil, ceftriaxone, cefazolin, and ceftibuten; and group C and D subjects underwent challenges with some of the aforementioned cephalosporins selected on the basis of their patterns of positivity.There were 73 subjects in group A, 13 in group B, 7 in group C, and 9 in group D. Challenges with alternative cephalosporins (ceftibuten in 101, cefazolin in 96, cefaclor in 82, and cefuroxime axetil and ceftriaxone in 22 subjects) were well tolerated.Cephalosporin hypersensitivity does not seem to be a class hypersensitivity. Subjects with cephalosporin allergy who especially require alternative cephalosporins might be treated with compounds that have side-chain determinants different from those of the responsible cephalosporins and have negative pretreatment skin test responses." @default.
• W2073164009 created "2016-06-24" @default.
• W2073164009 creator A5009321100 @default.
• W2073164009 creator A5013045967 @default.
• W2073164009 creator A5028337298 @default.
• W2073164009 creator A5031608553 @default.
• W2073164009 creator A5040116193 @default.
• W2073164009 creator A5045393594 @default.
• W2073164009 creator A5086279442 @default.
• W2073164009 date "2015-09-01" @default.
• W2073164009 modified "2023-09-26" @default.
• W2073164009 title "IgE-mediated hypersensitivity to cephalosporins: Cross-reactivity and tolerability of alternative cephalosporins" @default.
• W2073164009 cites W1441666804 @default.
• W2073164009 cites W1983156767 @default.
• W2073164009 cites W1990798615 @default.
• W2073164009 cites W1994606543 @default.
• W2073164009 cites W2000102343 @default.
• W2073164009 cites W2004768827 @default.
• W2073164009 cites W2005245159 @default.
• W2073164009 cites W2005251828 @default.
• W2073164009 cites W2007679918 @default.
• W2073164009 cites W2036477427 @default.
• W2073164009 cites W2042715670 @default.
• W2073164009 cites W2043732926 @default.
• W2073164009 cites W2048852491 @default.
• W2073164009 cites W2052951012 @default.
• W2073164009 cites W2055792929 @default.
• W2073164009 cites W2059554755 @default.
• W2073164009 cites W2061754999 @default.
• W2073164009 cites W2064010761 @default.
• W2073164009 cites W2073704218 @default.
• W2073164009 cites W2074883034 @default.
• W2073164009 cites W2075032257 @default.
• W2073164009 cites W2078456401 @default.
• W2073164009 cites W2079109782 @default.
• W2073164009 cites W2079602083 @default.
• W2073164009 cites W2096606953 @default.
• W2073164009 cites W2098026142 @default.
• W2073164009 cites W2108511018 @default.
• W2073164009 cites W2111840635 @default.
• W2073164009 cites W2133931711 @default.
• W2073164009 cites W2144236549 @default.
• W2073164009 cites W2146797844 @default.
• W2073164009 cites W2158847388 @default.
• W2073164009 cites W2162515376 @default.
• W2073164009 cites W4232794167 @default.
• W2073164009 cites W4243807236 @default.
• W2073164009 cites W4250901028 @default.
• W2073164009 cites W4255577185 @default.
• W2073164009 doi "https://doi.org/10.1016/j.jaci.2015.03.012" @default.
• W2073164009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25930196" @default.
• W2073164009 hasPublicationYear "2015" @default.
• W2073164009 type Work @default.
• W2073164009 sameAs 2073164009 @default.
• W2073164009 citedByCount "116" @default.
• W2073164009 countsByYear W20731640092015 @default.
• W2073164009 countsByYear W20731640092016 @default.
• W2073164009 countsByYear W20731640092017 @default.
• W2073164009 countsByYear W20731640092018 @default.
• W2073164009 countsByYear W20731640092019 @default.
• W2073164009 countsByYear W20731640092020 @default.
• W2073164009 countsByYear W20731640092021 @default.
• W2073164009 countsByYear W20731640092022 @default.
• W2073164009 countsByYear W20731640092023 @default.
• W2073164009 crossrefType "journal-article" @default.
• W2073164009 hasAuthorship W2073164009A5009321100 @default.
• W2073164009 hasAuthorship W2073164009A5013045967 @default.
• W2073164009 hasAuthorship W2073164009A5028337298 @default.
• W2073164009 hasAuthorship W2073164009A5031608553 @default.
• W2073164009 hasAuthorship W2073164009A5040116193 @default.
• W2073164009 hasAuthorship W2073164009A5045393594 @default.
• W2073164009 hasAuthorship W2073164009A5086279442 @default.
• W2073164009 hasConcept C126322002 @default.
• W2073164009 hasConcept C197934379 @default.
• W2073164009 hasConcept C2776520383 @default.
• W2073164009 hasConcept C2776905138 @default.
• W2073164009 hasConcept C2777050379 @default.
• W2073164009 hasConcept C2777514703 @default.
• W2073164009 hasConcept C2778353156 @default.
• W2073164009 hasConcept C2778375690 @default.
• W2073164009 hasConcept C2778719061 @default.
• W2073164009 hasConcept C2779631663 @default.
• W2073164009 hasConcept C2779766023 @default.
• W2073164009 hasConcept C2780463255 @default.
• W2073164009 hasConcept C501593827 @default.
• W2073164009 hasConcept C64778159 @default.
• W2073164009 hasConcept C71924100 @default.
• W2073164009 hasConcept C86803240 @default.
• W2073164009 hasConcept C89423630 @default.
• W2073164009 hasConcept C94665300 @default.
• W2073164009 hasConceptScore W2073164009C126322002 @default.
• W2073164009 hasConceptScore W2073164009C197934379 @default.
• W2073164009 hasConceptScore W2073164009C2776520383 @default.
• W2073164009 hasConceptScore W2073164009C2776905138 @default.
• W2073164009 hasConceptScore W2073164009C2777050379 @default.
• W2073164009 hasConceptScore W2073164009C2777514703 @default.
• W2073164009 hasConceptScore W2073164009C2778353156 @default.
• W2073164009 hasConceptScore W2073164009C2778375690 @default.

• next